{"schema_version":"1.0","type":"article","title":"讓大藥廠心動的管線到底做了什麼？","url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.md","lang":"zh-Hant","date":"2026-05-05","publish_at":"2026-05-05T10:30:00+08:00","updated_at":"2026-05-05","category":"商業分析系列","topic":"商業分析系列","tags":["Dcard","免費文章","BD","GLP-1","ADC","CNS","FDA","藥華藥"],"summary":"📌 醫藥產業的併購邏輯，正在發生一場非常明顯的結構性變化。過去幾年，許多 Biotech 都想往最大、最熱門、最容易被資本市場理解的賽道擠：腫瘤、ADC、自體免疫、GLP-1、雙抗、細胞治療。這些方向","key_points":[],"facts":[],"sections":["01｜2026 年 Q1 的異常繁榮，真正釋放的是「精準掃貨」訊號","02｜為什麼小眾與罕見，反而成了大爆款？","03｜真正讓 MNC 無法拒絕的 PoC，不是「漂亮」，而是「去風險」","04｜買方焦慮：專利懸崖下，MNC 要的是「即插即用」","05｜給 early-stage Biotech 的啟示：不要再用大而散的管線圖感動自己","06｜台灣可以聯想到誰？不是硬套，而是看「窄賽道、清楚數據、全球化能力」"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/","source":"","date":"","url":"https://www.reuters.com/legal/transactional/eli-lilly-buy-centessa-pharma-63-billion-deal-2026-03-31/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-greenlights-first-ever-treatment-rare-metabolic-disorder-2025-03-26/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Rolling Submission of New Drug ...\"","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：讓大藥廠心動的管線到底做了什麼？","url":"https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-01.webp"},{"alt":"Dcard 原圖：讓大藥廠心動的管線到底做了什麼？","url":"https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-02.png"},{"alt":"Dcard 原圖：讓大藥廠心動的管線到底做了什麼？","url":"https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-05）。讓大藥廠心動的管線到底做了什麼？。https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-05-pharma-pipeline-bd-attraction-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}